



Correction: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2023)

Accepted: 19 September 2023 / Published online: 21 October 2023
© Springer Nature Switzerland AG 2023

Correction: Aging Clinical and Experimental Research (2023) 35:S37–S613
<https://doi.org/10.1007/s40520-023-02442-7>

In the published article references were missing for the abstracts listed below and incorrect authors' initials have been updated.

P323 ASSESSMENT AND REHABILITATION OF HAND DEFICITS WITH THE USE OF BOX AND BLOCK TEST IN AUGMENTED REALITY ENVIROMENT

References:

1. Kontson K et al. PLoS One 2017;12:e0177965.
2. Canny ML et al. Am J Occup Ther 2009;63:506.
3. Desrosiers J et al. Arch Phys Med Rehab 1994;75:751.
4. Zhang F et al. (2020) <https://arxiv.org/abs/2006.10214>
5. Zestas ON et al. <https://doi.org/10.1109/PACET56979.2022.9976370>.
6. Nagamune K, Tsuzuki Y (2019) https://doi.org/10.1007/978-3-030-23560-4_43.
7. Everard G et al. J NeuroEngineering Rehabil 2022;19:7.
8. Phan HL et al. Appl Sci 2022;12:1848.

and

P321 QUANTIFICATION OF ASWORTH SCALE WITH THE USE OF PRESSURE SENSORS

G. Matsopoulos

N. Tselikas

O. Zestas

V. Protopappas

D. Fotiadis

References:

1. Ad P et al. Clin Rehabil 1999;13:373.
2. Ansari NN et al. Physiother Theory Pract 2008;24:205.

3. MacDonald, Matthew; Szpuszta, Mario (2005). Pro ASP.NET 2.0 in C# 2005 (1st ed.). Apress. ISBN 1–59,059-496–7.

4. Blazor-Build Client Web Apps With C#, <https://dotnet.microsoft.com/en-us/apps/aspnet/web-apps/blazor>, Accessed 23/01/2023.

5. Meseguer-Henarejos AB et al. Eur J Phys Rehabil Med 2018;54:576.

6. Li F et al. Eur J Phys Rehabil Med 2014;50:9.

P123 GAUCHER DISEASE ASSOCIATED WITH SEVERE OSTEOPOROSIS

References:

1. Dumitrascu MC, et al. Exp Ther Med. 2021;22(2):804.
 2. Paduraru DN, et al. Chirurgia 2019;114(5):564–70.
 3. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.
 4. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
 5. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
- P124 HYPER IMMUNOGLOBULIN IGM SYNDROME ASSOCIATED WITH SEVERE OSTEOPOROSIS

References:

1. Dumitrascu MC, et al. Exp Ther Med. 2021;22(2):804.
2. Paduraru DN, et al. Chirurgia 2019;114(5):564–70.
3. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.
4. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
5. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
6. Ghemigian A, et al. Exp Ther Med 2021;22(5):1219.
7. Gheorghisan-Galateanu AA, et al. J Pak Med Assoc 2017;67(6):917–22.

P130 SEVERE OSTEOPOROSIS COMPLICATED WITH MULTIPLE RIB FRACTURES IN A PATIENT WITH MULTIPLE MYELOMA

References:

The original article can be found online at <https://doi.org/10.1007/s40520-023-02442-7>.

1. Popescu M, et al. *Rom J Morphol Embryol.* 2022;63(1):39–48.
 2. Radu L, et al. *Revista de Chimie* 2018;69(10):2754–8.
 3. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61
 4. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 4. Ghemigian A, et al. *Exp Ther Med* 2021;22(5):1219.
 5. Gheorghisan-Galateanu AA, et al. *J Pak Med Assoc* 2017;67(6):917–22
 7. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
P133 THE TIMELINE OF BONE MINERAL DENSITY VALUES AS CLUE FOR PRIMARY HYPERPARATHYROIDISM

References:

1. Popescu M, et al. *Rom J Morphol Embryol.* 2022;63(1):39–48.
 2. Radu L, et al. *Revista de Chimie* 2018;69(10):2754–8.
 3. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 4. Gheorghisan-Galateanu AA, et al. *J Pak Med Assoc* 2017;67(6):917–22.
 5. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
 6. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

P142 LONG TERM DXA FOLLOW-UP ON A PATIENT WITH OSTEOPOROSIS: DECISION OF DRUG HOLIDAY

References:

1. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 2. Popescu M, et al. *Rom J Morphol Embryol.* 2022;63(1):39–48.
 3. Radu L, et al. *Revista de Chimie* 2018;69(10):2754–8.
 4. Gheorghisan-Galateanu AA, et al. *J Pak Med Assoc* 2017;67(6):917–22.
 5. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
 6. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

P170 SUPPRESSIVE LEVOTHYROXINE THERAPY AND PRIMARY HYPERPARATHYROIDISM: DECISION FOR FRACTURE RISK REDUCTION—ASSOCIATED TREATMENT

References:

1. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.
 2. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 3. Popescu M, et al. *Rom J Morphol Embryol.* 2022;63(1):39–48.
 4. Radu L, et al. *Revista de Chimie* 2018;69(10):2754–8.
 5. Gheorghisan-Galateanu AA, et al. *J Pak Med Assoc* 2017;67(6):917–22.
 6. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.

P178 ANALYZING BONE TURNOVER MARKERS IN NEWLY DETECTED THYROTOXICOSIS

References:

1. Gheorghisan-Galateanu AA, et al. *J Pak Med Assoc* 2017;67(6):917–22.
 2. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.
 3. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 4. Popescu M, et al. *Rom J Morphol Embryol.* 2022;63(1):39–48.
 5. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
 6. Radu L, et al. *Revista de Chimie* 2018;69(12):3483–5.
P180 DECISION OF ANTI-OSTEOPOROTIC MEDICATION IN AN ELDERLY FEMALE WITH BREAST MALIGNANCY

References:

1. Ghemigian A, et al. *Exp Ther Med* 2021;22(5):1219.
 2. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.
 3. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 4. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.
 5. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
 6. Radu L, et al. *Revista de Chimie* 2018;69(12):3483–5.
P192 MALE OSTEOPOROSIS: ENDOCRINE CONSIDERATIONS ON NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM

References:

1. Ghemigian A, et al. *Exp Ther Med* 2022;23(1):88.
 2. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.
 3. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 4. Ghemigian A, et al. *Exp Ther Med* 2021;22(5):1219.
 5. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.
 6. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
P202 ANTI-RESORPTIVE TREATMENT AND BREAST CANCER: REAL-LIFE-MEDICINE ASPECTS

References:

1. Gheorghisan-Galateanu AA, et al. *Acta Endocrinologica-Bucharest* 2017;13(3):356–63.
 2. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.
 3. Ghemigian A, et al. *Exp Ther Med* 2021;22(5):1219.
 4. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.
 5. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.
 6. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

P206 FEMORAL NECK OSTEOPOROTIC FRACTURE IN A PATIENT WITH OSTEOPENIA AT CENTRAL DXA SCAN

References:

1. Radu L, et al. *Revista de Chimie* 2018;69(12):3483–5.
 2. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.
 3. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.

4. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.

5. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

6. Gheorghisan-Galateanu AA, et al. *Acta Endocrinologica-Bucharest* 2017;13(3):356–63.

P209 ADDITIONAL CONTRIBUTORS TO OSTEOPENIA IN AN ELDERLY

References:

1. Albulescu DM, et al. *Revista de Chimie* 2018;69(12):3683–7.

2. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

3. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.

4. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

5. Gheorghisan-Galateanu AA, et al. *Acta Endocrinologica-Bucharest* 2017;13(3):356–63.

6. Dumitru N, et al. *Rom J Int Med* 2019;57(1):61–7.

P221 CONSIDERATIONS OVER LONG TERM HISTORY OF EARLY HYPOGONADISM-ASSOCIATED OSTEOPOROSIS AND NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM

References:

1. Sandru F, et al. *Exp Ther Med* 2020;20(4):3389–93.

2. Ghemigian A, et al. *Exp Ther Med* 2021;22(5):1219.

3. Albulescu DM, et al. *Revista de Chimie* 2018;69(12):3683–7.

4. Popescu M, et al. *Revista de Chimie* 2018;69(8):2089–91.

5. Gheorghisan-Galateanu AA et al. *J Pak Med Assoc* 2020;70(1):129–33.

6. Bechir ES, et al. *Revista de Chimie* 2018;69(12):3565–8.

P223 FAST BONE LOSER PHENOTYPE IN EARLY MENOPAUSE

References:

1. Sandru F, et al. *Exp Ther Med* 2020;20(4):3389–93.

2. Albulescu DM, et al. *Revista de Chimie* 2018;69(12):3683–7.

3. Popescu M, et al. *Revista de Chimie* 2018;69(8):2089–91.

4. Bechir ES, et al. *Revista de Chimie* 2018;69(12):3565–8.

5. Tuculina MJ, et al. *Romanian Journal of Oral Rehabilitation* 2022;14(1):78–85.

6. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

P235 HYPERCALCEMIA IN A PATIENT WITH BASEDOW-GRAVES' DISEASE: IS THERE ANY OTHER CAUSE?

References:

1. Tuculina MJ, et al. *Romanian Journal of Oral Rehabilitation* 2022;14(1):78–85.

2. Popescu AD, et al. *Diagnostics(Basel)* 2022;12(11):2772.

3. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

4. Bugăla NM, et al. *Diagnostics(Basel)* 2022;12(9):2080.

5. Dumitru N, et al. *Rom J Int Med* 2019;57(1):61–7.

6. Nedeltcheva-Petrova E, et al. *Rom J Military Med* 2022;125(1):157–61.

P236 BONE STATUS IN A PATIENT WITH SURGICALLY INDUCED MENOPAUSE

References:

1. Sandru F, et al. *Exp Ther Med* 2020;20(4):3389–93.

2. Tuculina MJ, et al. *Romanian Journal of Oral Rehabilitation* 2022;14(1):78–85.

3. Popescu AD, et al. *Diagnostics(Basel)* 2022;12(11):2772.

4. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

5. Sandru F, et al. *Rom J Military Med* 2020;123(3):166–71.

6. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.

P247 COVID-19 PANDEMIC IMPACT ON ADHERENCE TO MEDICATION AGAINST OSTEOPOROSIS

References:

1. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.

2. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

3. Dumitru N, et al. *Rom J Int Med* 2019;57(1):61–7.

4. Nicola AG, et al. *Diagnostics(Basel)* 2022;12(9):2168.

5. Popescu M, et al. *Diagnostics(Basel)* 2022;12(4):960.

6. Sandru F, et al. *Exp Ther Med* 2021;22(1):756.

P250 THE IMPACT OF BISPHOSPHONATES DRUG HOLIDAY ON LONG TERM PRIMARY FEMALE OSTEOPOROSIS

References:

1. Sandru F, et al. *Exp Ther Med* 2020;20(4):3389–93.

2. Peretianu D, et al. *Rom J Military Med* 2022;125(3):515–22.

3. Sandru F, et al. *Rom J Military Med* 2020;123(3):166–71.

4. Albulescu DM, et al. *Revista de Chimie* 2018;69(12):3683–7.

5. Ghemigian A, et al. *Exp Ther Med* 2022;23(1):88.

6. Tuculina MJ, et al. *Romanian Journal of Oral Rehabilitation* 2022;14(1):78–85.

P256 COMPLICATED PRIMARY OSTEOPOROSIS AND OSTEOPENIA AT DXA

References:

1. Sandru F, et al. *Exp Ther Med* 2020;20(4):3383–8.

2. Dumitru N, et al. *Rom J Int Med* 2019;57(1):61–7.

3. Sandru F, et al. *Rom J Military Med* 2020;123(3):166–71.

4. Albulescu DM, et al. *Revista de Chimie* 2018;69(12):3683–7.

5. Tuculina MJ, et al. *Exp Ther Med* 2022;23(4):288.

6. Popescu M, et al. *Rom J Morphol Embryol* 2022;63(1):39–48.

P257 OSTEOPOROSIS IN PATIENT WITH PRIMARY HYPERPARATHYROIDISM AND INSULIN DEPENDENT TYPE 2 DIABETES MELLITUS

References:

1. Nedeltcheva-Petrova E et al. Rom J Military Med 2022;125(1):157–61.
2. Peretianu D, et al. Rom J Military Med 2022;125(3):515–22.
3. Tuculina MJ, et al. Romanian Journal of Oral Rehabilitation 2022;14(1):78–85.
4. Dumitru N, et al. Rom J Int Med 2019;57(1):61–7.
5. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
6. Sandru F, et al. Rom J Military Med 2020;123(3):166–71.

P263 BONE TURNOVER MARKERS PROFILE IN A MALE WITH NEWLY DETECTED THYROTOXICOSIS AND TYPE 2 DIABETES MELLITUS

References:

1. Sandru F, et al. Rom J Military Med 2020;123(3):166–71.
2. Popescu M, et al. Revista de Chimie 2018;69(8):2089–91.
3. Dumitru N, et al. Rom J Int Med 2019;57(1):61–7.
4. Albulescu DM, et al. Revista de Chimie 2018;69(12):3683–7.
5. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
6. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.

P266 PREMATURE OVARIAN FAILURE AND OSTEOPOROSIS

References:

1. Sandru F, et al. Rom J Military Med 2020;123(3):166–71.
2. Popescu M, et al. Revista de Chimie 2018;69(8):2089–91.
3. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
4. Gheorghisan-Galateanu AA, et al. Acta Endocrinologica-Bucharest 2017;13(3):356–63.
5. Ghemigian A, et al. Exp Ther Med 2022;23(1):88.
6. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.
7. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.

P273 BETWEEN TRAUMATIC AND OSTEOPOROTIC FRACTURE

References:

1. Popescu M, et al. Revista de Chimie 2018;69(8):2089–91.
2. Gheorghisan-Galateanu AA, et al. Acta Endocrinologica-Bucharest 2017;13(3):356–63.
3. Ghemigian A, et al. Exp Ther Med 2022;23(1):88.
4. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
5. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.
6. Dumitru N, et al. Rom J Int Med 2019;57(1):61–7.
7. Tuculina MJ, et al. Romanian Journal of Oral Rehabilitation 2022;14(1):78–85.

P291 FROM LUMBAR PAIN TO CUSHING'S SYNDROME FOLLOWED BY CUSHING'S SYNDROME

COMPLICATED WITH LUMBAR VERTEBRAL FRACTURES AND ASSOCIATED PAIN

References:

1. Sandru F, et al. Exp Ther Med 2020;20(4):3383–8.
2. Popescu M, et al. Revista de Chimie 2018;69(8):2089–91.
3. Ghemigian A, et al. Exp Ther Med 2022;23(1):88.
4. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.
5. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
6. Bugăla NM, et al. Diagnostics(Basel) 2022;12(9):2080.
7. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.

P585 PANDEMIC DRUG HOLIDAY: A NEW ENTITY IN REAL-LIFE-MEDICINE?

References:

1. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
2. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
3. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.
4. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.
5. Popescu M, et al. Diagnostics(Basel) 2022;12(4):960.

P623 SUPPRESSED PARATHORMON LEVELS AND HIGH BONE TURNOVER MARKERS IN NEWLY DETECTED HYPERTHYROIDISM: HOW FAR SHOULD WE GO TO INVESTIGATE IT?

References:

1. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.
2. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
3. Popescu M, et al. Diagnostics (Basel) 2022;12(4):960.
4. Tuculina MJ, et al. Exp Ther Med 2022;23(4):288.
5. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.

P745 MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 SYNDROME AND OSTEOPOROSIS

References:

1. Sandru F, et al. Exp Ther Med 2021;22(1):756.
2. Popescu M, et al. Rom J Morphol Embryol. 2022;63(1):39–48.
3. Nedeltcheva-Petrova E, et al. Rom J Military Med 2022;125(1):157–61.
4. Popescu M, et al. Diagnostics(Basel) 2022;12(4):960.
5. Bechir ES et al. Revista de Chimie 2018;69(12):3565–8.

P879 OSTEOGENESIS IMPERFECTA IN A POST-MENOPAUSE OSTEOPOROTIC PATIENT—CASE REPORT

References:

1. Stanciu M et al. Medicine (Baltimore) 2019;98:14,154.
2. Pavel OR et al. Rom J Morphol Embryol 2016;57:121.
3. Popa FL et al. Rom J Lab Med 2016;24:75.

P326 OSTEOPOROSIS IN PATIENTS WITH CHRONIC AUTOIMMUNE THYROIDITIS

References:

- Popa FL, Stanciu M, Bighea A, Berteanu M, Totoianu I Gh, Rotaru M. Decreased serum levels of sex steroids associated with osteoporosis in a group of Romanian male patients. *Romanian Journal of Laboratory Medicine*, Vol 24, nr 1, pp 75–82; <https://doi.org/10.1515/rml-2016-0014>; 2016.
- Stanciu M, Bera LG, Popescu M, Grosu F, Popa LF. Hashimoto's thyroiditis associated with thyroid adenoma with Hurthle cells-case report. *Rom J Morphol Embryol*; 58(1):241–248; 2017.
- Stanciu M, Zaharie IS, Bera LG, Cioca G. Correlations between the presence of Hurthle cells and cytomorphological features of fine-needle aspiration biopsy in thyroid nodules. *Acta Endo (Buc)* vol. 12, nr. 4, pp 485–490; <https://doi.org/10.4183/aeb.2016.485>, 2016.

The original article has been updated.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.